Krsnaa Diagnostics Ltd (KRSNAA)

📊 Quarterly Results (₹ Cr)

Quarterly revenue shows a clear upward trend, rising from ₹193 crore in September 2025 to ₹236 crore in June 2026, reflecting 22% YoY growth in Q1 FY27 driven by retail expansion and infrastructure wins such as the 34-center Himachal PPP project. However, operating margins have compressed to 12.8% in June 2026 from 17.3% in September 2025, primarily due to front-loaded investments in Rajasthan, even as management expects this capex to drive future scale. Net profit and EPS have fluctuated quarter-on-quarter, with June 2026 showing ₹17 crore net profit and ₹5.1 EPS, down from ₹42 crore and ₹12.86 EPS in March 2026, indicating that profitability is being sacrificed temporarily for expansion.

🔮 Management Outlook & What's Next

Management targets double-digit margins by year-end and projects Rajasthan PPP revenue to reach ₹100-150 crores annually, with RPL EBITDA expected to turn positive by Q2. Retail contribution is expected to rise from 9% to 10-15% of sales this fiscal, supported by infrastructure wins and AI diagnostics adoption across 18 states. Accreditations (NABL/NABH) across multiple states are being leveraged as scalable quality benchmarks to support national expansion. These initiatives are framed as part of an asset-light growth model designed to drive sustainable margins and scalable revenue without immediate dilution.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet shows a steady increase in total assets from ₹1,282 crore in March 2025 to ₹1,824 crore in March 2026, reflecting ongoing capital investment, primarily in infrastructure and expansion. Borrowings have risen from ₹166 crore to ₹534 crore over the same period, indicating increased leverage to fund growth initiatives. Equity remains stable at ₹16 crore, with reserves growing from ₹867 crore to ₹964 crore, suggesting that retained earnings and capital reserves are being used to absorb expansion costs rather than equity dilution. This pattern aligns with a capital-intensive growth phase supported by debt and internal reserves.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Promoter holding has remained stable at 27.11% across filings, but the proposed convertible warrant issue aims to increase it to 30.58% post-allotment, reinforcing promoter control. FII holdings have fluctuated slightly, declining from 4.28% in Q1FY27 to 3.91% in Q4FY26, while DII holdings have risen from 13.86% to 14.51% over the same period, indicating growing institutional interest. The number of public shareholders has increased from 52,117 to 53,625, suggesting broader retail participation. No promoter pledging or significant dilution events are evident, and the shareholding pattern remains stable with no signs of exit by key investors.

⚖️ Peer Comparison — Healthcare

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. Execution risk in scaling retail and PPP projects: Management cites infrastructure wins like the Himachal PPP, but delays or cost overruns in similar projects (e.g., Rajasthan) could delay revenue realization and margin recovery. 2. Margin compression persistence: Operating margins have declined sequentially despite revenue growth, and if front-loaded capex does not yield timely returns, profitability may remain pressured beyond the current fiscal year. 3. Regulatory and compliance exposure: The company’s growth strategy relies on complex regulatory approvals and SEBI compliance for its preferential issue; any delays or scrutiny could disrupt capital-raising plans. 4. Market sentiment sensitivity: With a 1Y return of -30.37% and a low P/E of 18.5, the stock is vulnerable to sentiment shifts, especially if expansion fails to deliver expected margins or revenue scalability.

📋 Recent Filings

• 🟡 Board Meeting2026-09-28Krsnaa Diagnostics held its 16th AGM on September 28, 2026 at Chinchwad, Pune, with 36 members present including all directors and KMPs. The meeting a…
• 🔴 Financial Results2026-09-28Krsnaa Diagnostics announced the board approved selling diagnostic equipment for up to **₹120 crores** to monetize non-core assets, aiming to improve …
• Announcement2026-09-19Krsnaa Diagnostics announced that its trading window will close on September 22, 2026, remaining shut until 48 hours after the unaudited Q2 results ar…
• 🔴 Announcement2026-09-16Krsnaa Diagnostics announced it has signed a 15-year PPP concession agreement with Punjab Health Systems Corporation to operate PET-CT diagnostic cent…
• 🔴 annual report2026-09-11Krsnaa Diagnostics informed shareholders that the FY2025-26 Annual Report is available via web link https://krsnaadiagnostics.com/2026-annual-report/ …
• 🟡 sustainability report2026-09-05Krsnaa Diagnostics Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26 to BSE and NSE on September 5, 2026, …
• 🟡 Board Meeting2026-09-05Krsnaa Diagnostics Limited announced its 16th Annual General Meeting will be held on Monday, September 28, 2026 at 11:00 Hrs. (IST) at its registered …
• 🔴 annual report2026-09-05Krsnaa Diagnostics reported FY2025-26 revenue of **₹7,343.59 crores**, profit of **₹1,026.75 crores**, and cash of **₹250.47 crores** at year-end. The…
• 🟡 voting results2026-08-28Krsnaa Diagnostics issued a corrigendum to its August 13, 2026 postal ballot notice, amending key details of the proposed preferential issue of share …
• Announcement2026-08-26Krsnaa Diagnostics disclosed an Income Tax rectification order for Assessment Year 2022-23 that revises the tax demand upward by Rs. 12.09 crore, incr…

🧠 Analyst's Read

Krsnaa Diagnostics is executing a capital-intensive expansion strategy supported by infrastructure wins and retail growth, but near-term profitability is being sacrificed for scale. Investors should monitor the progress of Rajasthan PPP revenue realization and the timing of margin recovery, as well as shareholder response to the convertible warrant issue, which could influence control dynamics and future capital allocation.

Based on filing content and financial data. Not a recommendation.